Statement Of Cash Flows [Abstract]

Innate Pharma - Filing #2821023

Concept As at
2020-12-31
2020-01-01 to
2020-12-31
2019-01-01 to
2019-12-31
As at
2019-12-31
As at
2018-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operating activities
51 767 EUR
34 924 EUR
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities
9,000 EUR
EUR
Purchase of property, plant and equipment, classified as investing activities
907,000 EUR
1 271 EUR
Purchase of intangible assets, classified as investing activities
10 375 EUR
64 130 EUR
Purchase of other long-term assets, classified as investing activities
59,000 EUR
10,000 EUR
Interest received, classified as investing activities
962,000 EUR
1 290 EUR
Cash flows from (used in) investing activities
13 370 EUR
62 121 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
48,000 EUR
44,000 EUR
Proceeds from borrowings, classified as financing activities
1 360 EUR
13 900 EUR
Interest paid, classified as financing activities
341,000 EUR
204,000 EUR
Cash flows from (used in) financing activities
1 177 EUR
77 765 EUR
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
219,000 EUR
5,000 EUR
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
66 096 EUR
50 572 EUR
Cash and cash equivalents
136 792 EUR
202 887 EUR
152 314 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.